{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:15:51Z","timestamp":1782220551545,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jiac.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T03:59:43Z","timestamp":1657943983000},"page":"1464-1470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan"],"prefix":"10.1016","volume":"28","author":[{"given":"Xingzhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Schmerold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-9930","authenticated-orcid":false,"given":"Toshio","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2022.07.005_bib1","series-title":"Global HIV & AIDS statistics \u2014 fact sheet","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.jiac.2022.07.005_bib2","series-title":"The annual report for 2020","year":"2021"},{"key":"10.1016\/j.jiac.2022.07.005_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174360","article-title":"The HIV care cascade: Japanese perspectives","volume":"12","author":"Iwamoto","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2022.07.005_bib4","series-title":"Treatment guidance for HIV infection","year":"2021"},{"key":"10.1016\/j.jiac.2022.07.005_bib5","series-title":"Guidelines for HIV treatment","year":"2021"},{"key":"10.1016\/j.jiac.2022.07.005_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/QAD.0b013e328340feb0","article-title":"Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research","volume":"25","author":"Bae","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2022.07.005_bib7","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/jac\/dkv083","article-title":"Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database","volume":"70","author":"Raffi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.07.005_bib8","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2147\/PPA.S207908","article-title":"Treatment adherence and persistence among HIV-1 patients newly starting treatment","volume":"13","author":"Hines","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jiac.2022.07.005_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s15010-020-01469-6","article-title":"Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005\u20132017","volume":"48","author":"Stecher","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2022.07.005_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jiac.2022.07.005_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/QAI.0000000000001481","article-title":"Increased persistence of initial treatment for HIV Infection with modern antiretroviral therapy","volume":"76","author":"Davy-Mendez","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2022.07.005_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3851\/IMP2287","article-title":"Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010","volume":"18","author":"Jarrin","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jiac.2022.07.005_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/s12879-019-4129-6","article-title":"Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database","volume":"19","author":"Ruzicka","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2022.07.005_bib14","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41598-022-05816-5","article-title":"Analysis of antiretroviral therapy switch rate and switching pattern for people living with HIV from a national database in Japan","volume":"12","author":"Naito","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2022.07.005_bib15","author":"Medical Data Vision Co","year":"2021"},{"key":"10.1016\/j.jiac.2022.07.005_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195789","article-title":"Treatment pathways of Japanese prostate cancer patients - a retrospective transition analysis with administrative data","volume":"13","author":"Cheung","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2022.07.005_bib17","series-title":"Culture, sports, science and technology","author":"Ministry of Education","year":"2014"},{"key":"10.1016\/j.jiac.2022.07.005_bib18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/phar.2246","article-title":"Integrase inhibitors: after 10 years of experience, is the best yet to come?","volume":"39","author":"Brooks","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2022.07.005_bib19","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/QAD.0b013e32830efd79","article-title":"Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy","volume":"22","author":"Willig","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2022.07.005_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/aid.2017.0203","article-title":"Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate-to a tenofovir alafenamide-based regimen through 96 weeks of treatment","volume":"34","author":"DeJesus","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jiac.2022.07.005_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hiv.12664","article-title":"Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials","volume":"19","author":"Hagins","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2022.07.005_bib22","series-title":"List of approved products","author":"Pharmaceuticals","year":"2022"},{"key":"10.1016\/j.jiac.2022.07.005_bib23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/QAI.0000000000002250","article-title":"Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting","volume":"83","author":"Greenberg","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2022.07.005_bib24","doi-asserted-by":"crossref","first-page":"ofz051","DOI":"10.1093\/ofid\/ofz051","article-title":"Risk and cost associated with drug\u2013drug Interactions among aging HIV patients receiving combined antiretroviral therapy in France","volume":"6","author":"Demessine","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2022.07.005_bib25","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jiac.2022.07.005_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/apc.2015.0199","article-title":"The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients","volume":"30","author":"Krentz","year":"2016","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jiac.2022.07.005_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019985","article-title":"Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database","volume":"8","author":"Ruzicka","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jiac.2022.07.005_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jiac.2018.10.006","article-title":"Greater burden of chronic comorbidities and co-medications among people living with HIV versus people without HIV in Japan: a hospital claims database study","volume":"25","author":"Ruzicka","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.07.005_bib29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/QAD.0b013e32835cb997","article-title":"the Antiretroviral Therapy Cohort C: durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and N. America 2002\u20132009","volume":"27","author":"Abgrall","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2022.07.005_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171227","article-title":"HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014","volume":"12","author":"H\u00e4ggblom","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2022.07.005_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3851\/IMP3194","article-title":"Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE)","volume":"23","author":"Martinez-Vega","year":"2018","journal-title":"Antivir Ther"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2200201X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2200201X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:04:09Z","timestamp":1761159849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2200201X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1341321X2200201X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.07.005","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}